Non-Invasive Solutions in Cancer
Second Opinion by Iylon
Working to Revolutionize Cancer Care Through Non-invasive Solutions
Cancer is a leading cause of death globally. Despite, decades of effort and aggressive cancer treatments, cancer remains a civilizational challenge.
Datar Cancer Genetics is a leader in developing blood-based diagnostics that can detect cancer early, offer non-invasive investigations for better treatment options, and track the progression of the disease or its recurrence.
We believe that relentless research, bold initiatives, sustained commitment, and an unapologetic determination to succeed against cancer will help us defeat it. We dedicate ourselves to this singular mission as if our life depends on it.
Today, liquid biopsy is an integral part of cancer detection and management. Our scientists have developed unique customized non-invasive tests by combining analysis of molecular biomarkers and the Circulating Tumor Cells (CTCs) to make personalized cancer management from liquid biopsy, a reality. Our tests make it possible to look at molecularly targeted therapies, and personalizing of treatments in the context of tumor heterogeneity and dynamic tumor biology.
The Revolutionary Changes
We Are Making in Cancer Care
Effect of Our Proprietary CEM
on Benign Cells, PBMCs
and Malignant Cells
of Circulating Tumor
Studies Show Blood Tests
Reveal Breast Cancer
Earlier Than Mammograms
CEM = CTC Enrichment Medium
PBMC = Peripheral Blood Mononuclear Cells
500 EastRidge, Perimeter Park,
North Carolina 27560. USA